Effect of Helicobacter pylori Infection on Barrett's Esophagus and Esophageal Adenocarcinoma Formation in a Rat Model of Chronic Gastroesophageal Reflux

Helicobacter

Volumn 16, Issue 1, 2011, Pages 66-77

  Liu, Fang Xun ^a   Wang, Wei Hong ^a   Wang, Jing ^a   Li, Jiang ^a   Gao, Pei Pei ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Animal model; Barrett's esophagus; Cyclooxygenase 2; Esophageal adenocarcinoma; Gastroesophageal reflux disease; Helicobacter pylori

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; MESSENGER RNA; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR CDX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BARRETT ESOPHAGUS; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGOJEJUNOSTOMY; ESOPHAGUS INJURY; ESOPHAGUS MUCOSA; EVALUATION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADENOCARCINOMA; ANASTOMOSIS, SURGICAL; ANIMALS; BARRETT ESOPHAGUS; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GENE EXPRESSION PROFILING; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTOCYTOCHEMISTRY; HOMEODOMAIN PROTEINS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TRANSCRIPTION FACTORS;

ANIMALIA; HELICOBACTER PYLORI; RATTUS;

EID: 78751529656     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00811.x     Document Type: Article

References (55)

1. Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 2003;98:1627-33.
2. Schmassmann A, Oldendorf MG, Gebbers JO. Changing incidence of gastric and oesophageal cancer subtypes in central Switzerland between 1982 and 2007. Eur J Epidemiol 2009;24:603-9.
3. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999;94:86-91.
4. Neumann H, Monkemuller K, Vieth M, Malfertheiner P. Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options. Dig Dis 2009;27:18-23.
5. Vieth M, Masoud B, Meining A, Stolte M. Helicobacter pylori infection: protection against Barrett's mucosa and neoplasia? Digestion 2000;62:225-31.
6. Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000;95:387-94.
7. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007;5:1413-7.
8. Ferrández A, Benito R, Arenas J, García-González MA, Sopeña F, Alcedo J, Ortego J, Sainz R, Lanas A. CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett's esophagus in a population with high H. pylori infection rate. BMC Gastroenterol 2006;6:7.
9. Blaser MJ, Perez-Perez GI, Lindenbaum J, Schneidman D, Van Deventer G, Marin-Sorensen M, Weinstein WM. Association of infection due to Helicobacter pylori with specific upper gastrointestinal pathology. Rev Infect Dis 1991;13(Suppl 8):S704-8.
10. Sirigu F, Capeccioni S, Dessi A, Masia AM. Helicobacter pylori in Barrett's esophagus and in normal or inflamed esophageal mucosa: a retrospective study. Riv Eur Sci Med Farmacol 1994;6:131-4.
11. Loffeld RJ, Ten Tije BJ, Arends JW. Prevalence and significance of Helicobacter pylori in patients with Barrett's esophagus. Am J Gastroenterol 1992;87:1598-600.
12. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-6.
13. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-96.
14. Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, Fushida S, Ohta T. [Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide]. Nippon Shokakibyo Gakkai Zasshi 2007;104:1183-91.
15. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122:1101-12.
16. Martins FP, Artigiani Neto R, Oshima CT, da Costa PP, Forones NM, Ferrari AP. Over-expression of cyclooxygenase-2 in endoscopic biopsies of ectopic gastric mucosa. Braz J Med Biol Res 2007;40:1447-54.
17. Toyoda M, Shirasaka D, Aoyama N, et al. Helicobacter pylori eradication therapy on histologic change in the distal esophagus. Helicobacter 2006;11:217-23.
18. Abdel-Latif MM, Windle H, Terres A, Eidhin DN, Kelleher D, Reynolds JV. Helicobacter pylori extract induces nuclear factor-kappa B, activator protein-1, and cyclooxygenase-2 in esophageal epithelial cells. J Gastrointest Surg 2006;10:551-62.
19. McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell 1992;68:283-302.
20. Villanacci V, Rossi E, Zambelli C, Galletti A, Cestari R, Missale G, Casa DD, Bassotti G. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus. Dig Liver Dis 2007;39:305-11.
21. Eda A, Osawa H, Satoh K, Yanaka I, Kihira K, Ishino Y, Mutoh H, Sugano K. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 2003;38:14-22.
22. Lord RV, Brabender, Wickramasinghe K, DeMeester SR, Holscher A, Schneider PM, Danenberg PV, DeMeester TR. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 2005;138:924-31.
23. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004;17:1392-9.
24. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-10.
25. Yu J, Tang BD, Leung WK, To KF, Bai AH, Zeng ZR, Ma PK, Go MY, Hu PJ, Sung JJ. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention. World J Gastroenterol 2005;11:41-5.
26. Miwa K, Sahara H, Segawa M, Kinami S, Sato T, Miyazaki I, Hattori T. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer 1996;67:269-74.
27. Lanas A, Royo Y, Ortego J, Molina M, Sainz R. Experimental esophagitis induced by acid and pepsin in rabbits mimicking human reflux esophagitis. Gastroenterology 1999;116:97-107.
28. Bhandari P, Bateman AC, Mehta RL, Patel P. Mucosal expression of cyclooxygenase isoforms 1 and 2 is increased with worsening damage to the gastric mucosa. Histopathology 2005; 46:280-6.
29. Ferrero RL, Thiberge JM, Labigne A. Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice. Gastroenterology 1997;113:185-94.
30. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997;112:1386-97.
31. Somi MH, Fattahi E, Fouladi RF, Karimi M, Bonyadi R, Baballou Z. An inverse relation between CagA+ strains of Helicobacter pylori infection and risk of erosive GERD. Saudi Med J 2008;29:393-6.
32. Kwon JH, Chung IS, Son HS, Park JM, Cho YK, Lee IS, Kim SW, Choi MG. [The relationship of gastrin, pepsinogen, and Helicobacter pylori in erosive reflux esophagitis]. Korean J Gastroenterol 2008;51:159-66.
33. Vaezi MF, Falk GW, Peek RM, Vicari JJ, Goldblum JR, Perez-Perez GI, Rice TW, Blaser MJ, Richter JE. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 2000;95:2206-11.
34. Zhang J, Chen XL, Wang KM, Guo XD, Zuo AL, Gong J. Relationship of gastric Helicobacter pylori infection to Barrett's esophagus and gastro-esophageal reflux disease in Chinese. World J Gastroenterol 2004;10:672-5.
35. Schutze K, Hentschel E, Dragosics B, Hirschl AM. Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut 1995;36:831-3.
36. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
37. Yagi S, Okada H, Takenaka R, Miyoshi M, Suzuki S, Toyokawa T, Kawahara Y, Yamamoto K. Influence of Helicobacter pylori eradication on reflux esophagitis in Japanese patients. Dis Esophagus 2009;22(4):361-7.
38. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, Williams C, Ardill JE, McColl KE. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15-24.
39. Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 1995;87:1777-80.
40. Ito S, Yoshihiro K, Kato T, Suzuki K, Fujiki N. [Correlation between Campylobacter pylori and chronic atrophic gastritis]. Nippon Shokakibyo Gakkai Zasshi 1990;87:1815-21.
41. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115:50-7.
42. Zhao CM, Wang X, Friis-Hansen L, Waldum HL, Halgunset J, Wadström T, Chen D. Chronic Helicobacter pylori infection results in gastric hypoacidity and hypergastrinemia in wild-type mice but vagally induced hypersecretion in gastrin-deficient mice. Regul Pept 2003;115:161-70.
43. Konturek PC, Brzozowski T, Konturek SJ, Stachura J, Karczewska E, Pajdo R, Ghiara P, Hahn EG. Mouse model of Helicobacter pylori infection: studies of gastric function and ulcer healing. Aliment Pharmacol Ther 1999;13:333-46.
44. J, Karczewska E, Hahn EG. Functional and morphological aspects of Helicobacter pylori-induced gastric cancer in Mongolian gerbils. Eur J Gastroenterol Hepatol 2003;15:745-54.
45. Bercik P, De Giorgio R, Blennerhassett P, Verdu EF, Barbara G, Collins SM. Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection. Gastroenterology 2002;123:1205-15.
46. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-90.
47. Tannaes T, Bukholm IK, Bukholm G. High relative content of lysophospholipids of Helicobacter pylori mediates increased risk for ulcer disease. FEMS Immunol Med Microbiol 2005;44:17-23.
48. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut 1997;40:9-13.
49. Wright TA, Myskow M, Kingsnorth AN. Helicobacter pylori colonization of Barrett's esophagus and its progression to cancer. Dis Esophagus 1997;10:196-200.
50. Henihan RD, Stuart RC, Nolan N, Gorey TF, Hennessy TP, O'Morain CA. Barrett's esophagus and the presence of Helicobacter pylori. Am J Gastroenterol 1998;93:542-6.
51. Watari J, Moriichi K, Tanabe H, Sato R, Fujiya M, Miwa H, Das KM, Kohgo Y. Differences in genetic instability and cellular phenotype among Barrett's, cardiac, and gastric intestinal metaplasia in a Japanese population with Helicobacter pylori. Histopathology 2009;55:261-9.
52. Moriichi K, Watari J, Das KM, Tanabe H, Fujiya M, Ashida T, Kohgo Y. Effects of Helicobacter pylori infection on genetic instability, the aberrant CpG island methylation status and the cellular phenotype in Barrett's esophagus in a Japanese population. Int J Cancer 2009;124:1263-9.
53. Sakai T, Fukui H, Franceschi F, Penland R, Sepulveda AR, Fujimori T, Terano A, Genta RM, Graham DY, Yamaoka Y. Cyclooxygenase expression during Helicobacter pylori infection in Mongolian gerbils. Dig Dis Sci 2003;48: 2139-46.
54. Kim SW, Jang TJ, Jung KH, Suh JI. Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats. Yonsei Med J 2007;48:1020-7.
55. Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, Fushida S, Ohta T, Koichi M. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis 2005;26:565-70.